MD434Z - Metodă de prognozare a evoluţiei uveitei endogene - Google Patents
Metodă de prognozare a evoluţiei uveitei endogene Download PDFInfo
- Publication number
- MD434Z MD434Z MDS20100208A MDS20100208A MD434Z MD 434 Z MD434 Z MD 434Z MD S20100208 A MDS20100208 A MD S20100208A MD S20100208 A MDS20100208 A MD S20100208A MD 434 Z MD434 Z MD 434Z
- Authority
- MD
- Moldova
- Prior art keywords
- uveitis
- course
- predicting
- evolution
- determined
- Prior art date
Links
- 206010046851 Uveitis Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 8
- 230000004913 activation Effects 0.000 claims abstract description 8
- 238000005119 centrifugation Methods 0.000 claims abstract description 4
- 230000002349 favourable effect Effects 0.000 claims abstract description 4
- 210000002966 serum Anatomy 0.000 claims abstract description 4
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000010241 blood sampling Methods 0.000 abstract 1
- 239000008279 sol Substances 0.000 description 7
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 4
- 108090000978 Interleukin-4 Proteins 0.000 description 4
- 229940028885 interleukin-4 Drugs 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 206010003267 Arthritis reactive Diseases 0.000 description 1
- 208000002691 Choroiditis Diseases 0.000 description 1
- 241000909851 Epiphora Species 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- 208000003971 Posterior uveitis Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 208000037855 acute anterior uveitis Diseases 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000016747 lacrimal apparatus disease Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000026475 palpebral edema Diseases 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20100208A MD434Z (ro) | 2010-12-01 | 2010-12-01 | Metodă de prognozare a evoluţiei uveitei endogene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| MDS20100208A MD434Z (ro) | 2010-12-01 | 2010-12-01 | Metodă de prognozare a evoluţiei uveitei endogene |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| MD434Y MD434Y (en) | 2011-11-30 |
| MD434Z5 MD434Z5 (ro) | 2012-06-30 |
| MD434Z true MD434Z (ro) | 2012-06-30 |
Family
ID=45815313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDS20100208A MD434Z (ro) | 2010-12-01 | 2010-12-01 | Metodă de prognozare a evoluţiei uveitei endogene |
Country Status (1)
| Country | Link |
|---|---|
| MD (1) | MD434Z (mo) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU764659A1 (ru) * | 1977-09-29 | 1980-09-23 | 2-Ой Московский Ордена Ленина Государственный Медицинский Институт Им. Н.И.Пирогова | Способ вы влени аллергического воспалени при увеите |
| SU1727074A1 (ru) * | 1989-11-14 | 1992-04-15 | Московский научно-исследовательский институт глазных болезней им.Гельмгольца | Способ прогнозировани рецидивов увеита |
| SU1734022A1 (ru) * | 1990-01-15 | 1992-05-15 | Астраханский государственный медицинский институт им.А.В.Луначарского | Способ оценки эффективности лечени увеитов |
| SU1783444A1 (ru) * | 1990-08-16 | 1992-12-23 | Mo Nii Tuberkuleza | Способ диагностики туберкулезного увеита |
| RU2157541C1 (ru) * | 1999-06-01 | 2000-10-10 | Дроздова Елена Александровна | Способ прогнозирования течения увеитов при системных и синдромных заболеваниях |
| MD1804G2 (ro) * | 1999-07-05 | 2002-06-30 | Константин ЖУКОВСКИЙ | Metodă de pronosticare a rezultatelor tratamentului chirurgical al glaucomului primar cu unghi deschis |
| MD3073G2 (ro) * | 2005-07-06 | 2007-01-31 | Наталия ЛУПАШКО | Metodă de prognozare a riscului apariţiei complicaţiilor inflamator-degenerative ale globului ocular după discizia cataractei secundare |
| RU2298188C1 (ru) * | 2005-09-19 | 2007-04-27 | Московский научно-исследовательский институт глазных болезней им. Гельмгольца | Способ прогнозирования неблагоприятного течения увеитов |
| MD3795G2 (ro) * | 2007-08-30 | 2009-08-31 | ЧЕРОЙДА Петру | Metodă de determinare a gradului de severitate al retinopatiei hipertensive |
-
2010
- 2010-12-01 MD MDS20100208A patent/MD434Z/ro not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MD434Y (en) | 2011-11-30 |
| MD434Z5 (ro) | 2012-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | Role of regulatory T cells in regulating fetal-maternal immune tolerance in healthy pregnancies and reproductive diseases | |
| Mouzaki et al. | Expression patterns of Th1 and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura (ITP) at presentation and their modulation by intravenous immunoglobulin G (IVIg) treatment: their role in prognosis | |
| Helfrich et al. | Normotensive renal failure in systemic sclerosis | |
| De Mos et al. | Current understandings on complex regional pain syndrome | |
| Dai et al. | IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells | |
| Brandt et al. | Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab | |
| Cortes-Cerisuelo et al. | Increased pretransplant frequency of CD28+ CD4+ TEM predicts belatacept-resistant rejection in human renal transplant recipients | |
| Su et al. | Impaired Tip60-mediated Foxp3 acetylation attenuates regulatory T cell development in rheumatoid arthritis | |
| Matsumoto et al. | Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure | |
| Yoo et al. | Recent advances in autoimmune thyroid diseases | |
| Huang et al. | Infliximab reduces CD147, MMP-3, and MMP-9 expression in peripheral blood monocytes in patients with active rheumatoid arthritis | |
| Xie et al. | ATRA alters humoral responses associated with amelioration of EAMG symptoms by balancing Tfh/Tfr helper cell profiles | |
| Li et al. | The efficacy of rituximab combined with 131I for ophthalmic outcomes of Graves' ophthalmopathy patients | |
| Okuda et al. | Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis | |
| Li et al. | Paeoniflorin ameliorates symptoms of experimental Sjogren's syndrome associated with down-regulating Cyr61 expression | |
| Shikama et al. | Involvement of adiponectin in age-related increases in tear production in mice | |
| Green et al. | Reversible insensitivity to androgens in men with untreated gluten enteropathy | |
| Shen et al. | Semaphorin 4D from CD15+ granulocytes via ADAM10-induced cleavage contributes to antibody production in bullous pemphigoid | |
| Wu et al. | Activation of the liver X receptor inhibits Th17 and Th1 responses in Behcet’s disease and Vogt-Koyanagi-Harada disease | |
| Parietti et al. | Rituximab treatment overcomes reduction of regulatory iNKT cells in patients with rheumatoid arthritis | |
| Li et al. | Identification of key mRNAs and microRNAs in the pathogenesis and progression of osteoarthritis using microarray analysis | |
| Wiltbank et al. | Abdominal pain in donors during filtration leukapheresis | |
| Biswas et al. | Intermediate uveitis of pars planitis type in identical twins | |
| Nussenblatt et al. | Altered suppressor-cell activities in uveitis | |
| Khan et al. | Uveitis in spondyloarthropathies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees | ||
| ND4Y | Validity of short term patent extended [from 6 to 10 years] |
Expiry date: 20201201 |
|
| KA4Y | Short-term patent lapsed due to non-payment of fees (with right of restoration) | ||
| MM4Y | Short-term patent definitely lapsed due to non-payment of fees |